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REDUCED-PROTEIN SUBUNIT VACCINE FOR 
SWINE DYSENTERY 
BACKGROUND OF INVENTION 
1. Field of Invention 
The ?eld of this invention relates to the production of 
a vaccine effective against swine dysentery, a disease of 
swine caused by an anaerobic spirochete, Treponema 
hyodysenteriae. 
2. Information Disclosure Statement 
T. hyodysenteriae (also known as Serpula’hyodysen 
teriae, see Stanton, et al., J. Sys. Bacteriol, 41:50-58 
(199l) has been recognized as the primary etiological 
agent of swine dysentery (1). Although pigs infected by 
T. hyodysenteriae may recover and be resistant to sub 
sequent infection by T. hyodysenteriae, efforts to in 
duce immunity by parenteral administration of killed 
cells of T. hyodysenteriae have met with limited success 
and are generally ineffective in ?eld use (2). Killed 
whole-cell T. hyodysenteriae bacterins have been de 
veloped, but often use mineral-oil base adiuvants (3) or 
have not involved pre-treatment of the T. hyodysen 
teriae cells to increase their effectiveness as a bacterin. 
The use of live avirulent strains of T. hyodysenteriae 
as a vaccine have also been unsuccessful in protecting 
affected pigs (4,5). Combinations of killed T. hyodysen 
teriae bacterins followed by live avirulent T. hyodysen 
teriae vaccines have also been attempted (6). 
Killed whole-cell bacterins based on T. hyodysen 
teriae cells produced by conventional methods have 
been produced and used in the ?eld. However, the 
efficacy of these preparations is typically low with vac 
cinates reported having 50% of the incidence of swine 
dysentery as unvaccinated controls (7). Other prepara 
tions of killed T. hyodysenteriae cells administered as 
bacterins have also had limited success, with death and 
clinical signs of swine dysentery reported in both the 
vaccinated and unvaccinated animals (8). 
A principal reason for the inadequate ef?cacy of 
vaccines studied to date may be the interference of 
other T. hyodysenteriae antigens with more function 
ally immunogenic antigens. A strongly immunogenic 
antigen which is not protective may be so much more 
immunogenic than a protective antigen that most of the 
host animal‘s immune response is directed against the 
nonprotective antigen, to the detriment of the host re 
sponse to the protective antigen. In other words, non 
functional antigens (those which do not provide disease 
resistance) may compete with functional antigens. 
Other reasons for this may be that the functional antigen 
is concealed by the nonfunctional antigen (sterically) or 
that antibody produced to the nonprotective antigen 
blocks the protective antigen which is thus not pro 
cessed by the host immune system. 
Treponema hyodysenteriae is a helical anaerobic 
spirochaete. As recently as 1988, researchers declared 
that “little information is available regarding the physi 
ology, cell biochemistry and nutrition” of this organism 
(13). 
Lipooligosaccharides (LOS) have been extracted 
with hot phenol-water from the other membranes of T. 
hyodysenteriae serotypes 1 through 7 (14). These LOSs 
have been used as an antigenic reagent in an‘ enzyme 
linked immunosorbent assay for the detection of anti 
bodies to 71 hyodysenteriae antigens (16). This left unre 
solved the question of whether the LOSs were protec 
tive antigens suitable for vaccine use. Moreover, some 
40 
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reports suggested that treponemal lipopolysaccharide 
was toxic. 
No admission is made that any of the references cited 
herein is prior art. The discussion of the references is 
based solely on their published content and is not bind 
ing on Applicants. 
SUMMARY OF INVENTION 
This invention is based on a method of increasing the 
effectiveness of killed preparations of T. hyodysen 
teriae. The method is practiced by the parenteral admin 
istration of a vaccine or bacterin containing as the ac 
tive immunizing agent T. hyodysenteriae cells and sub 
cellular components which have been pretreated to 
reduce the protein content of the T. hyodysenteriae 
components. Whole cells which may be grown in any of 
several recognized media and under conditions recog 
nized in prior art are treated to reduce the amount 'of 
protein from the T. hyodysenteriae cells and subcellular 
components present in the preparation. This reduced 
protein preparation is then administered by parenteral 
injection to swine, preferably before they are infected 
with T. hyodysenteriae. 
The equivalent of 5 X109 killed cells of T. hyodysen 
teriae treated to reduce the protein content of the bac 
terin or vaccine is suf?cient to reduce death and mor 
'bidity due to swine dysentery caused by T. hyodysen 
teriae infection. The protection against both death and 
morbidity due to swine dysentery caused by T. hyody 
senteriae infection which is provided by the reduced-_ 
protein vaccine or bacterin is superior to that noted 
with similar preparations of killed T. hyodysenteriae 
cells or subcellular components which have not been 
pretreated to reduce the protein content. 
The exact nature of the antigen immune response is 
unknown, although a systemic response to the LOS- or 
LPS-like component of T. hyodysenteriae cells by both 
the cellular and humoral immune systems of the swine is 
likely to be involved. This immune response to the 
LPS-like component of T. hyodysenteriae cells is likely 
to be enhanced by the reduction in extraneous proteins 
from T. hyodysenteriae cells and other sources which 
may interfere in the elicitation of a speci?c immune 
response to the LPS-like component of T. hyodysen 
teriae (9). 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS 
The treponema outer membrane may be extracted 
with sodium-N-lauryl sarcosinate (sarcosine) or Triton 
X-lOO. Other chaotropic agents may also be employed. 
The apparent molecular weights of the predominant 
proteins in the range 22-49 kDa in Triton X-lOO prepa 
rations of T. hyodysenteriae B204, as determined from 
polyacrylamide gels stained with Coomassie Blue after 
SDS-PAGE, were as follows (15): 
44.9: 1.4 
43.6: 1.2 
42.3: 1.3 
40.8: 1.6 
38.7: 1.4 
35.9: 1.3 
33.7: 1.6 
31.6: 1.5 
30.0:0.9 
29.0: 1.1 
26.6:0.9 
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There is an OM component in the 14-19 kDa range 
that does not stain with coomassie blue‘but can be sil 
ver-stained. 
The majority of the proteins in the 22.5 to 46.5 kDa 
range could be surface labeled, but there was no detect 
able label in the 14-19 kDa range. Immunoblot analysis 
of variously treated OM preparations revealed that the 
antigenic epitopes were resistant to proteinase-K, beta 
glucuronidase, neuraminidase and trypsin, but sensitive 
to periodate, suggesting that they were carbohydrate in 
nature (15). 
Some components of the lipopolysaccharides of T 
hyodysenteriae have been tentatively identi?ed by gas 
liquid chromatography, based on their retention times. 
The sugars include fucose, galactose, glucose, glucos 
amine, heptose, mannose, rhamnose and a thiobarbitaric 
acid-reactive component 2-Keto-3-deoxyoctonate. The 
fatty acids included myristic acid, l3-methyl-myristic 
acid, and 3-hydroxy-hexadecanoic acid. 
The outer membrane also includes endotoxins which 
can be extracted with trichloroacetic acid or with buta 
nol-water (a). The endotoxins are about 11% protein. 
In one embodiment, the present invention is directed 
to a vaccine preparation derived from T. hyodysenteriae 
in which the protein content has been substantially 
reduced, so that a statistically signi?cant reduction in 
morbidity (bloody scours) is observed in pigs chal 
lenged after vaccination. Preferably, the product con 
tains less than 1 ug/ml intact protein of 5-8,000 daltons 
or above. Generally speaking, if the preferred product 
is analyzed by SDS-PAGE, silver staining of the gel 
will be unable to detect immunogenic >5,000 daltons. 
Treponema hyodysenteriae strains (both virulent and 
avirulent) are available from United States and foreign 
culture depositories and from private culture collec 
tions. Several different serotypes (currently seven) of T. 
hyodysenteriae are known to exist and to cause swine 
dysentery in susceptible animals. Methods for the isola 
tion of T. hyodysenteriae have been described in the 
literature (10). Suitable isolates include strain number 
31212 (or B204) of serotype 2 from the American Type 
Culture Collection (a, 11). However, any isolate of T. 
hyodysenteriae capable of causing disease in swine is 
suitable for the practice of this invention. 
Treponema hyodysenteriae cells may be grown in 
either solid or liquid growth media. Trypticase soy 
broth (TSB) with 7.5% horse serum (HS) 0.5% yeast 
extract, VPI anaerobe salts (l2) and 0.05% L-cysteine is 
suitable for preparing T. hyodysenteriae cells for the 
practice of this invention, although other suitable media 
are known in the literature (13). T. hyodysenteriae cells 
are grown anaerobically or microaerophillically in re 
duced oxygen atmospheres at temperatures of 35°-40° 
C. (13). After growth, T. hyodysenteriae cells may be 
killed by standard methods such as formalin, merthio 
late or heat treatment (although merthiolate is pre 
ferred) and collected by centrifugation or ultra?ltra 
tion. The T. hyodysenteriae cells may also be killed by 
the process of lysing the cells which may be performed 
by physical means such as pressure treatment or sonica 
tion or by changes in the pH or tonicity of the surround 
20 
25 
30 
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ing medium. The extraction of the outer membrane is ‘ 
not necessary, but is permissible. 
After suitable T. hyodysenteriae cells are prepared 
and lysed, they are treated to reduce the protein content 
of the preparation. Such a reduction in the protein con 
tent may be accomplished by treatment with protein 
65 
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degrading enzymes such as proteinase-K. It should be 
understood that many protein-degrading enzymes are 
known in the literature and any enzyme or physical or 
chemical treatment which results in a signi?cant reduc‘ 
tion in the protein content of the preparation (without 
adversely affecting immunogenicity of the product) is 
suitable for the practice of this method. The speci?c 
conditions of temperature, pH and other physical values 
under which the protein-reduction occurs is dependent 
on the enzyme or protein-reducing system employed. 
For example, if proteinase-K is used, a commercial 
proteinase'K preparation is added to the cell and lysed 
cell suspension which is then incubated at 56° C. for two 
hours and 37° C. for an additional twelve hours. 
The reduced-protein suspension is preferably derived 
from at least about 5X 109 T. hyodysenteriae cells per 
dose comprises the vaccine, although levels of antigen 
equal to at least 1 X IOIOT. hyodysenteriae cells per does 
are more preferred. This preparation may be mixed 
with various adjuvant preparations known in the litera 
ture such as mineral oils, metabolizable organic oils, 
emulsi?ers or metal salts to enhance the effectiveness of 
the vaccine. While mineral oils are not preferred, as 
they are potential carcinogens and may also cause ad 
verse reactions, they may be used if desired. It should be 
understood that while the use of various adjuvant prep 
arations may enhance the effectiveness of this or any 
vaccine their use is not necessary to the practice of this 
method. 
The vaccine prepared by the practice of this method 
is administered to swine parenterally, generally by in 
tramuscular or subcutaneous injection. The vaccine is 
most effective if administered to swine which are other 
wise healthy and not already showing symptoms of 
swine dysentery. The vaccine is preferably adminis 
tered in a series of at least two doses separated by two 
three weeks, but other immunization schedules may be 
ef?cacious and may be determined by conventional 
means. 
The method of this invention is further illustrated by 
the following experimental examples. 
EXAMPLE 1 
A strain of Treponema hyodysenteriae serotype 2 
isolated from swine and designated as B-204 was grown 
in pure culture in a liquid medium consisting of trypti 
case soy broth supplemented with 5.0% horse serum 
(HS) 0.5% yeast extract, VPI anaerobe salts (12) and 
0.05% L-cysteine. This culture was grown at 39° C. in 
an atmosphere of 10% CO2, 10% H2 and 80% N; for 12 
hours by which time the majority of the growth of T. 
hyodysenteriae had ceased. The T. hyodysenteriae cells 
were then killed by the addition of l:l0,000 merthiolate. 
These killed cells were then collected by centrifugation 
at 20,000Xg for 45 minutes and resuspended in sterile 
0.85% saline after which they were lysed by the appli 
cation of pressure in a French pressure cell (5,000 psi) 
and the cell membranes of the lysed T. hyodysenteriae 
cells collected by centrifugation of the lysate at 
100,000Xg for 2 hours. This membrane material was 
resuspended in sterile phosphate-buffered 0.85% saline 
(pH 7.2) and treated with protease type XI-S (protei 
nase-K) at 56° C. for 2 hours followed by further incu 
bation at 37° C. for 12 hours. After protease treatment 
the 7‘. hyodysenteriae subcellular components were 
stored at 4° C. and comprised the concentrated vaccine. 
The concentrated vaccine was mixed with 25% 
Freund’s Incomplete Adjuvant (FIA) to form a water 
5,236,708 
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in-oil-in-water emulsion for injection into test animals. 
Similar preparations were made with whole-cell un 
treated T. hyodysenteriae cells in FIA and untreated T 
hyodysenteriae cell membranes in FIA to test the effec 
tiveness of the protein-reduction method. 
The reduced-protein preparation were tested for 
6 
ropsied. Samples were taken of the intestinal contents of 
the spiral colon and the cecum for re-isolation of Trepo 
nema hyodysenteriae. Lesions typical of swine dysen 
tery were recorded during necropsy. 
5 The results of the post-challenge observations of all 
groups are outlined in Table 2. - 
TABLE 2 
Post-Challeng Observations of-Vaccinated and Control Pigs 
# MID MID Mortal- T. 
Group Treatment Pigs Total Scour ADG ity hyo' 
l Reduced-Protein 4 0.0% 0.0% 0.98 lb/day 0% 0/4 
2 Whole-Cell 4 7.2% 0.0% 0.47 lb/day 0% l/4 
3 Membrane 4 16.1% 16.1% 0.87 lb/day 0% 3/4 
4 CONTROL 4 33.1% 2l.7% 0.94 lb/day 0% 2/4 
‘Treponema hyodysenteriae reisolated from feces. Number of pigs with Treponema hyodysenteriae/number of 
pigs in group. 
Total morbidity, all observed symptom. Equals (total number of days with symptoms/total number of pig 
days) x lOO. 
Morbidity with scours only. Difference from total morbidity is chie?y weakness and quantness counted in 
the total MID column. 
outer membrane protein content by sodium-dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS 
PAGE) assay with untreated T. hyodysenteriae mem 
branes as a control. For a suitable protocol, see Merrill, 
et al., Science, 211:1437 (1981). The untreated T. hyody 
senteriae membranes had many protein bands evident in 
the gel after silver staining while only three protein 
bands could be noted in the reduced-protein T. hyody 
senteriae membranes. This indicates that the majority of 
the native or natural T. hyodysenteriae membrane prote 
ins were reduced by the proteinase K treatment to a 
level below the ability of the SDS-PAGE/silver stain 
assay to detect speci?c proteins. 
Sixteen SPF (Speci?c Pathogen Free) swine from a 
herd known to be free of swine dysentery were weighed 
and used to test these preparations. Pigs were randomly 
assigned to groups. Four pigs were given the equivalent 
of 4X 1010 T. hyodysenteriae cells per dose of reduced 
protein vaccine in FIA in two doses two weeks apart. 
Four pigs were given whole cell T. hyodystneriae un 
treated by proteinase K in doses of 2x10‘0 T. hyody 
senteriae cells per dose in FIA in two doses two weeks 
apart. Four pigs were given membranes untreated by 
proteinase K in the equivalent of 4X1010 T. hyodysen 
teriae cells per dose of T. hyodysenteriae vaccine in 
FIA in two doses two weeks apart. These experimental 
groups are outlined in Table 1. 
TABLE 1 
Experimental Groups of Treatment 
Number 
Group of pigs Vaccine Doses 
1 4 2 X Reduced-Protein 2 doses 
' Membrane 2 weeks apart 
2 4 1 X Whole Untreated Cells 2 doses 
2 weeks apart 
3 4 2 X Untreated Membranes 2 doses 
2 weeks apart 
4 4 None (controls) None 
Ten days after the second vaccination all experimen 
tal pigs were fasted for 24 hours, re-weighed and chal 
lenged with l.69>< l0ll actively-growing, motile Trepo 
nema hyodysenteriae cells by oral inoculation. Unvac 
cinated control pigs were in continuous contact with 
the vaccinated pigs both before and after challenge. All 
pigs were observed daily for 21 days after challenge and 
any signs of swine dysentery (eg. bloody diarrhea) were 
recorded. At the end of the 21 day observation period, 
all surviving pigs were re-weighed, sacri?ced and nec 
25 
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Results 
Bloody diarrhea typical of swine dysentery (MID 
scour) was observed in unvaccinated control animals on 
21.7% of the daily observations. Bloody diarrhea was 
also noted in 16.1% of the daily observations of pigs 
receiving a vaccine consisting of Treponema hyodysen 
teriae membranes which had not been treated by the 
protein reduction method. Pigs receiving whole cell 
untreated Treponema hyodysenteriae had no bloody 
diarrhea. None of the four pigs receiving reduced 
protein T. hyodysenteriae vaccine had bloody diarrhea 
typical of swine dysentery. These data clearly demon 
strate that the reduced-protein T. hyodysenteriae vac 
cine was superior in reducing the incidence of bloody 
scours typical of swine dysentery as compared to un 
vaccinated control pigs. Further, the protection against 
bloody diarrhea was signi?cantly greater than that 
noted in untreated whole-cell Treponema hyodysen 
teriae vaccines prepared according to reported methods 
(7). 
This protection also extended to increased average 
daily weight gains in pigs receiving reduced-protein T. 
hyodysenteriae vaccine (0.98 lbs/day) as compared to 
pigs receiving classical killed, untreated whole-cell T. 
hyodysenteriae vaccine (0.47 lb/day), although controls 
were not as severely affected in this test. 
Treponema hyodysenteriae was re-isolated after chal 
lenge from two of four unvaccinated control pigs (50%) 
and one of four pigs receiving classical killed, untreated 
whole-cell T. hyodysenteriae vaccine (25). However, 
T. hyodysenteriae was not reisolated from any of the 
four pigs receiving reduced-protein T. hyodysenteriae 
vaccine. 
These data clearly demonstrate that a reduced 
protein T. hyodysenteriae vaccine made according to 
the method in this claim protects pigs vaccinated with 
such a preparation against the symptoms of swine dys 
entery (bloody diarrhea), weight loss due to T. hyody 
senteriae infection and re-isolation of T. hyodysen 
teriae. Further, this protection is notably superior not 
only to unvaccinated control pigs but also to killed 
whole cell or membrane T. hyodysenteriae vaccines 
made according to the prior art. The method of reduc 
ing the protein content of T. hyodysenteriae vaccines 
prior to administration to swine clearly results in en 
hanced protection of swine to swine dysentery due to 
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Treponema hyodysenteriae infection which is superior 
to that heretofore available. 
Example 2 
A strain of Treponema hyodysenteriae serotype 2 
isolated from swine and designated as 13-204 was grown 
in pure culture in a liquid medium consisting of trypti 
case soy broth supplemented with 7.5% horse serum 
(HS) 0.5% yeast extract, VPI anaerobe salts (12) and 
0.05% L-cysteine. This culture was grown at 2° C. in 
an atmosphere of 5% CO2, 10% H2 and 85% N; for 8 
hours by which time the majority of the growth of T. 
hyodysenteriae had ceased. The T. hyodysenteriae cells 
were then killed by the addition of 1:10,000 merthiolate. 
These killed cells were then collected by centrifugation 
at 20,000><g for 45 minutes and resuspended in sterile 
0.85% saline after which they were lysed by the appli 
cation of pressure in a French pressure cell (5,000 psig) 
and the cell membranes of the lysed T. hyodysenteriae 
cells collected by centrifugation of the lysate at 
100,000Xg for 2 hours. This membrane material was 
resuspended in sterile Phosphate-buffered 0.85% saline 
(pl-I 7.2) and treated with protease type XI-S (protei 
nase-K) at 56° C. for 2 hours followed by further incu 
bation at 37° C. for 12 hours. After protease treatment 
the T. hyodysenteriae subcellular components were 
stored at 4° C. and comprised the concentrated vaccine. 
The concentrated vaccine was mixed with 25% 
Freund‘s Incomplete Adjuvant (FIA) to form a water 
in-oil-in-water emulsion for injection into test animals. 
Similar preparations were made with whole-cell un 
treated T. hyodysenteriae cells in FIA and untreated T. 
hyodysenteriae cell membranes in FIA to test the effec 
tiveness of the protein-reduction method. 
The reduced-protein preparation was tested for outer 
membrane protein content by sodium-dodecyl-sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) assay 
with untreated T. hyodysenteriae membranes as a con 
trol. The untreated T. hyodysenteriae membranes had 
many protein bands evident in the gel after silver stain 
ing while only three protein bands could be noted in the 
reduced-protein T hyodysenteriae membranes. This 
indicates that the majority of the native or natural T. 
hyodysenteriae membrane proteins were reduced by 
the proteinase K treatment to a level below the ability 
of the SDS-PAGE/silver stain assay to detect speci?c 
proteins. 
Thirty SPF (Speci?c Pathogen Free) swine from a 
herd known to be free of swine dysentery were weighed 
and used to test these preparations. Pigs were randomly 
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assigned to groups. Six pigs were given the equivalent 
of 2X 1010 T. hyodysenteriae cells per does of reduced 
protein vaccine in FIA in two doses three weeks apart. 
Six pigs were given whole cell T. hyodysenteriae un 
treated by proteinase K in doses of 2X 1010 T. hyody 
senteriae cells per dose in FIA in two doses three weeks 
apart. Six pigs were given membranes untreated by 
proteinase K in the equivalent of 2X l0l0 T. hyodysen 
teriae cells per dose of T. hyodysenteriae vaccine in 
FIA in two doses three weeks apart. To test the dose/ 
response of the reduced-protein vaccine, groups of two 
pigs each were given 4X, iX or iX the dose of reduced 
protein vaccine in FIA in two doses three weeks apart. 
All experimental animals were housed together in one 
large room and were fed and handled identically. These 
experimental groups are outlined in Table 3. 
Table 3 
Experimental Groups and Treatments 
Group Number Vaccine 
of Pigs 
l 2 4 X Reduced-Protein Membranes 
2 6 l X Reduced-Protein Membranes 
3 2 1/2 X Reduced-Protein Membranes 
4 2 1/4 X Reduced-Protein Membranes 
5 6 l X Whole Untreated Cells 
6 6 1 X Untreated Membranes 
7 6 None (controls) 
In each of groups 1-6, two doses of the vaccine were 
administered 3 weeks apart. 
Eight days after the second vaccination all experi 
' mental pigs were fasted for 24 hours, re-weighed and 
challenged with 5 Xl01°actively-growing, motile Trep 
onema hyodysenteriae cells by oral inoculation. This 
challenge was repeated the next day (day nine after the 
second vaccination). As all pigs were housed together, 
the unvaccinated control pigs were in continuous 
contact with the vaccinated pigs both before and after 
challenge. All pigs were observed daily for 25 days 
after the second challenge and any signs of swine dysen 
tery (eg. bloody diarrhea) were recorded. At the end of 
the 25 day observation period, all surviving pigs were 
re-weighed, sacri?ced and necropsied. Samples were 
taken of the intestinal contents of the spiral colon, ileo 
cecal ori?ce and the cecum for re-isolation of Trepo 
nema hyodysenteriae. Lesions typical of swine dysen 
tery were recorded during necropsy. , 
The results of the post-challenge observations of all 
groups are outlined in Table 4. 
TABLE 4 
Post-Challenge Observations of Vaccinated and Control Pigs 
MID‘ MID 
# # # Bloody Bloody Scours T. hyo ADG" 
Vaccine Pigs Dead Scours Scours (Other) Reisolated lb/day 
Protein- 2 0 0 0% 8.0% l(50%) 0.86 
reduced (0%) (0%) 
membrane 
4 X 
Protein- 6 O 0 0% 0.0% 0(O%) 0.91 
reduced (0%) (0%) 
membrane 
1 X 
Protein- 2 O 0 0% 0.0% 0(0%) 0.70 
reduced (0%) (0%) 
membrane 
l X 
Protein- 2 l l’ 5.4% 0.0 l(50%) 0.40 
reduced (50%) (50%) 
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TABLE 4-continued 
Post-Challenge Observations of Vaccinated and Control Pigs 
MID‘ MID 
# # # Bloody Bloody Scours T. hyo ADO" 
Vaccine Pigs Dead Scours Scours (Other) Reisolated lb/day 
membrane 
i X 
Whole 6 l 2 7.5% 8.8% 3(50%) 0.63 
Cell (17%) (33%) - 
Membrane 6 0 5 16.7% 4.7% 5(83%) 0.39 
(0%) (83%) 
Control 6 1 5 29.6% 6.3% 3(50%) 0.37 
(17%) (83%) 
‘Morbidity Incidence and Duration. Equals (number of days with bloody diarrhea/total number of days 
since challenge to sacri?ce or death) X 100. 
Morbidity Incidence and Duration. Equals (number of days with diarrhea other than bloody diarrhea/total 
number of days since challenge to sacri?ce or death) X 100. 
ge)/number of days challenge to sacri?ce or death. In pounds gained per day. 
Results 
Bloody diarrhea typical of swine dysentery was ob 
served in 5/6 (83%) of the unvaccinated control ani 
mals. Bloody diarrhea was also noted in 5/6 (83%) of 
pigs receiving a vaccine consisting of Treponema 
hyodysenteriae membranes which had not been treated 
by the protein reduction method. Two of six (33%) pigs 
receiving whole cell untreated Treponema hyodysen 
teriae had bloody diarrhea. However, none of the ten 
pigs receiving reduced-protein T. hyodysenteriae vac 
cine at either the 4X, 1X or 5X doses had bloody diar 
rhea typical of swine dysentery. When the reduced 
protein T. hyodysenteriae vaccine was reduced to l of 
a dose, one of the two pigs receiving this vaccine had 
bloody diarrhea, indicating a dose-response to the re 
duced-protein T. hyodysenteriae vaccine. These data 
clearly demonstrate that the reduced-protein T. hyody 
senteriae vaccine was superior in reducing the inci 
dence of bloody scours typical of swine dysentery as 
compared to unvaccinated control pigs. Further, the 
protection against bloody diarrhea was signi?cantly 
greater than that noted in untreated whole-cell Trepo 
nema hyodysenteriae vaccines prepared according to 
the previous art (7). 
This protection also extended to increased average 
daily weight gains in pigs receiving reduced-protein T. 
hyodysenteriae vaccine (0.91 lbs/day)?as compared to 
untreated controls (0.37 lbs/day) or pigs receiving clas 
sical killed, untreated whole-cell T. hyodysenteriae 
vaccine (0.63 lb/day). Death loss was reduced 100% in 
pigs receiving reduced-protein T. hyodysenteriae vac 
cine as compared to deaths noted in pigs receiving both 
untreated whole-cell vaccine and no vaccine (controls). 
Pigs receiving 1X reduced protein vaccine (group 3) 
were protected against challenge as measured by aver 
age daily weight gain (p=0.065) and reduced morbidity 
(Bloody Scours) (p=0.007). Pigs given iX reduced 
protein vaccine (group 4) were protected against chal 
lenge as measured by reduced morbidity (Bloody 
Scours) (p=0.088) but not average daily weight gain 
(p=0.317). Pigs given iX reduced protein vaccine 
(group 5) were not signi?cantly protected against chal 
lenge as measured by reduced morbidity (Bloody 
Scours) (p=0.24l) or average daily weight gain 
(p=0.739). All analysis was by the Kruskal-Wallis one 
' way analysis of variance. Thus, the reduced protein 
vaccine offers statistically signi?cant protection at con 
centration of at least about QX. The product contained 
less than 1 ug/ml protein of 5-8,000 Da or above when 
used. 
20 
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' "Average Daily Weight Gain. Equals (weight at time of sacri?ce or death minus weight at time of challen 
Treponema hyodysenteriae was re-isolated after chal 
lenge from three of six unvaccinated control pigs (50%) 
and three. of six pigs receiving classical killed, untreated 
whole-cell T. hyodysenteriae vaccine (50%). However, 
T. hyodysenteriae was only reisolated from one of ten 
pigs receiving 4X, 1X or 5X reduced-protein T. hyody 
senteriae vaccine. 
These data clearly demonstrate that a reduced 
protein T. hyodysenteriae vaccine made according to 
the method in this claim protects pigs vaccinated with 
such a preparation against the symptoms of swine dys 
entery (death loss, bloody diarrhea), weight loss due to 
Treponema hyodysenteriae infection and re-isolation of 
Treponema hyodysenteriae. Further, this protection is 
notably superior not only to unvaccinated control pigs 
but also to killed whole cell or membrane T. hyodysen 
teriae vaccines made according to the prior art. The 
method of reducing the protein content of T. hyodysen 
teriae vaccines prior to administration to swine clearly 
results in enhanced protection of swine to swine dysen 
tery due to Treponema hyodysenteriae infection which 
is superior to that heretofore available. 
Tables 5, 6 and 7 further show the advantage of the 
Proteinease K digest over whole cell lysate and endo 
toxin preparations. In Table 5, we see a higher cecal 
weight and increased freedom from gross lesions. Table 
6 reveals that the number of T. hyodysenteriae recovered 
from vaccinated mice following challenge is most re 
duced by the PK digest. Finally, Table 7 shows a ten 
dency toward a lower number of colony forming units. 
TABLE 5 
Protection of Mice from Infection with 
Treponema hyodysenteriae Following Immunization 
Animal Clinical cecal dark ?eld 
Treatment no. signs“ weight" microscopy” 
Saline 1 NGL 0.24 N.D. 
2 XM 0.19 + 2 
3 N61. 0.30 N.D. 
4 XM8zAt 0.13 + 2 
5 XM&At 0.10 + 3 
6 XM 0.23 + l 
7 NGL 0.32 - N.D. 
Avg 0.22 i 0.08 
Whole Cell 8 N01. 0.18 N.D. 
Lysate 9 NGL 0.24 N.D. 
10 XM 0.13 + 2 
l 1 XM 0.18 N.D. 
l2 NGL 0.26 + 1 
13 XM 0.18 + 2 
l4 NGL 0.20 N.D. 
Avg 0.20 i 0.04 
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TABLE 5-continued 
Protection of Mice from Infection with 
Treponema hyodysenteriae Following Immunization 
Animal Clinical cecal dark ?eld 
Treatment no. signs” weightb microscopy‘ 
Endotoxine 15 XM 0.23 +1 
16 NGL 0.23 N.D. 
l7 NGL 0.24 N.D. 
18 NGL 0.36 ND. 
19 XM 0.20 +1 
20 NGL 0.22 ND. 
21 XM 0.21 N.D. 
Avg 0.24 i 0.05 
PK Digest] 22 NGL 0.18 ND. 
23 NGL 0.24 ND. 
24 NGL 0.22 ND. 
25 NGL 0.29 ND. 
26 NGL 0.27 ND. 
27 NGL 0.22 N.D. 
Avg 0.24 :t 0.04 
"Clinical signs of the disease were de?ned as the presence of excess Intraiminal 
mucus (XM). atrophy of the cecum (At) or no gross lesions (NGL . Two weeks 
following the last immunization, mice were challenged with 5 X 10 T. hyodysen 
teriae B204 on two consecutive days and then sacri?ced 10 days later. 
‘The weight of each cecum is expressed in grams. 
'Cecal contents were observed by dark ?eld microscopy for the presence of spiro 
chetes and given a relative score from +1 to +3 if spirochetes were observed or 
“N.D." if none were detected. 
dMice were interperitoneally immunized three times (two weeks apart) with 50 pg 
(protein content) of a whole cell lysate prepared from T. hyodysenteriae B204. 
'Mice were immunized (ip) three times with 50 pg of endotoxin (butanol/water 
extract) from T. hyodsenteriae B204. 
ice were immunized (ip) three times with a proteinase K digested whole cell 
lysate (equivalent to 50 pg of the whole cell lysate). 
TABLE 6 
Number of Treponema hyodysenteriae recovered from 
vaccinated mice following Challenge. 
Treatment!’ 11‘ CFUd 
Saline 7 4.1 i 2.2 X 106 
Whole Cell Lysate 7 2.5 r. 1.1 x 106 
ElldOlOXil'l 7 1.1 i 0.5 x 106 
Proteinase K Digest 6 5.0 i- 0.5 X 105 
0Mice challenged on two consecutive days with 5 X 106 T. hyodysenteriae and 
sacri?ced 10 days later. 
ice were immunized as described for Table 1. 
‘Number of mice per group. 
dColony forming units (CFU) of T. hyodysenteriae per gram of cecal tissue. 
Colony forming units of 
T. hyodysenteriae recovered from infected mice. 
Treatment No. DFb Culture CFUd 
Saline l — + 2.1 X 104 
2 ++ + 5.3 X 106 
3 — + 1.7 x 104 
4 ++ + 6.9 x 106 
5 + + + + 1.6 X 107 
6 + + 7.0 >< 105 
7 - + 9.4 X 104 
Whole Cell 8 — + 1.1 X 105 
Lysated 9 - + 8.3 x 104 
10 ++ + 2.5 x 106 
11 - + 5.3 x 106 
12 + + 7.7 x 106 
13 ++ + 1.4 >< 1o6 
14 - + 1.0 X 105 
Endotoxin 15 + + 1.3 x 106 
16 - - o 
17 - + 8.3 x 104 
18 ~ + <1.o X 104 
19 + + 4.0 x 106 
2o - + 1.8 x 105 
21 - + 2.0 x 106 
Proteinase K 22 - + <1.o X 104 
Digest 23 - + <1.0 x 104 
24 » + 2.3 x 10‘ 
25 - + <1.0 X 104 
26 - + 3.1 >< 1o6 
27 - + 4.5 x 104 
"Mice were vaccinated as described for Table 1. 
bPresence (+ ) or absence (-) of spirochetes in cecal contents as determined by dark 
?eld microscopy (DF). 
‘Cecal content were directly cultured on blood agar media for the detection of 
B-hemolytic spirochetes. 
‘Ceca were excised from each mouse. weighed, and homogenized. The homogenate 
was serially diluted and the number of colony forming units (CFU) of T. hyodysen 
teriae per gram cecum was determined. 
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We claim: 
1. A vaccine comprising an immunogenic preparation 
derived from Treponema hyodysenteriae cells and having 
a substantially reduced intact outer membrane protein 
content relative to said cells, said vaccine providing a 
statistically signi?cant reduction in morbidity due to 
T reponema hyodysenteriae infection in pigs immunized 
with said vaccine prior to said infection, and a pharma~ 
ceutically acceptable carrier. 
2. The vaccine of claim 1, said vaccine being further 
characterized in that it provides a greater reduction in 
morbidity than that provided by a killed whole cell 
Treportema hyodysenteriae vaccine. 
3. The vaccine of claim 1, wherein the protein con 
tent was enzymatically reduced. 
4. The vaccine of claim 3, wherein the enzyme has 
the characteristic substrate speci?city of proteinase K. 
5. The vaccine of claim 1, wherein the preparation is 
derived from an outer membrane extract of Treponema 
hyodysenteriae cells. 
6. A method of increasing the resistance of swine to 
T reponema hyodysenzerz'ae which comprises administer 
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ing to susceptible swine a vaccinologically effective 
amount of a vaccine according to claim 1. 
7. A method of increasing the resistance of swine to 
T reponema hyodysenteriae which comprises administer 
ing to susceptible swine a vaccinologically effective 
amount of a vaccine according to claim 2. 
8. A method of increasing the resistance of swine to 
Treponema hyodysenteriae which comprises administer 
ing to susceptible swine a vaccinologically effective 
amount of a vaccine according to claim 3. 
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9. A method of increasing the resistance of swine to 
T reponema hyodysenteriae which comprises administer 
ing to susceptible swine a vaccinologically effective 
amount of a vaccine according to claim 4. 
10. A method of increasing the resistance of swine to 
T reponema hyodysenteriae which comprises administer 
ing to susceptible swine a vaccinologically effective 
amount of a vaccine according to claim 5. 
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